Veracyte - VCYT Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for Veracyte's stock. Their VCYT share price forecasts range from $31.00 to $59.00. On average, they expect the company's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $41.20 at the beginning of 2022. Since then, VCYT stock has decreased by 59.2% and is now trading at $16.82.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VCYT earnings forecast.

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The biotechnology company had revenue of $72.86 million for the quarter, compared to the consensus estimate of $67.37 million. Veracyte had a negative net margin of 18.13% and a negative trailing twelve-month return on equity of 4.05%.

Veracyte updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $272.00 million-$280.00 million, compared to the consensus revenue estimate of $272.42 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.40%), State Street Corp (7.19%), Artisan Partners Limited Partnership (5.37%), Sumitomo Mitsui Trust Holdings Inc. (4.09%), Nikko Asset Management Americas Inc. (4.09%) and Pictet Asset Management SA (2.02%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $16.82.

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.20 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The company employs 761 workers across the globe.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.